230 related articles for article (PubMed ID: 33401297)
1. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study.
Hellgren K; Ballegaard C; Delcoigne B; Cordtz R; Nordström D; Aaltonen K; Gudbjornsson B; Love TJ; Aarrestad Provan S; Sexton J; Zobbe K; Kristensen LE; Askling J; Dreyer L
Rheumatology (Oxford); 2021 Aug; 60(8):3656-3668. PubMed ID: 33401297
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
3. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study.
Cordtz RL; Askling J; Delcoigne B; Smedby KE; Baecklund E; Ballegaard C; Isomäki P; Aaltonen K; Gudbjornsson B; Love TJ; Provan SA; Michelsen B; Sexton J; Dreyer L; Hellgren K
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36564101
[TBL] [Abstract][Full Text] [Related]
4. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
[TBL] [Abstract][Full Text] [Related]
5. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
[TBL] [Abstract][Full Text] [Related]
6. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study.
Rotar Z; Svetina P; Tomsic M; Hočevar A; Prapotnik S
BMJ Open; 2020 Feb; 10(2):e034356. PubMed ID: 32029494
[TBL] [Abstract][Full Text] [Related]
9. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
Lund Hansen R; Schoedt Jørgensen T; Dreyer L; Hetland ML; Glintborg B; Askling J; Di Giuseppe D; Jacobsson LTH; Wallman JK; Nordstrom D; Aaltonen K; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Love TJ; Kristensen LE
Rheumatology (Oxford); 2021 Jan; 60(1):140-146. PubMed ID: 32591790
[TBL] [Abstract][Full Text] [Related]
12. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
[TBL] [Abstract][Full Text] [Related]
13. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
Christensen IE; Lillegraven S; Mielnik P; Bakland G; Loli L; Sexton J; Uhlig T; Kvien TK; Provan SA
Ann Rheum Dis; 2022 Mar; 81(3):398-401. PubMed ID: 34625404
[TBL] [Abstract][Full Text] [Related]
14. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
[TBL] [Abstract][Full Text] [Related]
16. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
17. Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries.
Glintborg B; Di Giuseppe D; Wallman JK; Provan SA; Nordström D; Hokkanen AM; Österlund J; Kristianslund E; Kvien TK; Gudbjornsson B; Hetland ML; Michelsen B; Jacobsson L; Askling J; Lindström U
Rheumatology (Oxford); 2023 Feb; 62(2):647-658. PubMed ID: 35723604
[TBL] [Abstract][Full Text] [Related]
18. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
[TBL] [Abstract][Full Text] [Related]
19. Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register.
Vieira-Sousa E; Eusébio M; Ávila-Ribeiro P; Khmelinskii N; Cruz-Machado R; Rocha TM; Bernardes M; Santos-Faria D; Silva JL; Santos H; Miguel C; Carvalho P; Costa T; Duarte AC; Meirinhos T; Nero P; Fonseca JE; Santos MJ
J Rheumatol; 2020 May; 47(5):690-700. PubMed ID: 31371659
[TBL] [Abstract][Full Text] [Related]
20. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
